{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    43,
    44,
    45,
    46,
    47,
    48,
    49,
    50,
    51,
    57,
    62,
    63,
    70
  ],
  "modelUsed": "gemini-3-flash-preview",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_llm_1",
        "definition": "Study treatment administration",
        "anchorType": "FirstDose",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Once bedside PG reaches <60 mg/dL, the insulin infusion is stopped and approximately 5 minutes later study drug is administered. Indicates Time = 0 min."
      },
      {
        "id": "anchor_1",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Screening\nPeriod"
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent"
      },
      {
        "id": "anchor_3",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure"
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_interval_5",
        "type": "Interval",
        "interval": "PT15M",
        "minObservations": 5,
        "sourceText": "Predose, 15, 30, \n60, 120, 240 min"
      },
      {
        "id": "rep_interval_9",
        "type": "Interval",
        "interval": "PT5M",
        "minObservations": 12,
        "sourceText": "Predose, 5, 10, 15, \n20, 25, 30, 40, 50, \n60, 90, 120, 240 \nmin"
      },
      {
        "id": "rep_interval_13",
        "type": "Interval",
        "interval": "PT15M",
        "minObservations": 4,
        "sourceText": "Predose, 15, 30, \n60, 120 min"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "-P28D",
        "endOffset": "-P2D",
        "sourceText": "Days -28\nto -2"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "sourceText": "Screening\nPeriod"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "sourceText": "washout \nperiod"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "sourceText": "2 days \nafter"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "sourceText": "6 hours after"
      },
      {
        "id": "rep_window_24",
        "type": "Continuous",
        "sourceText": "4 hours after"
      },
      {
        "id": "rep_llm_1",
        "type": "Interval",
        "startOffset": "PT0M",
        "endOffset": "PT90M",
        "interval": "PT5M",
        "minObservations": 19,
        "exitCondition": "Completion of the 90-minute post-dose observation period",
        "sourceText": "Plasma Glucose Values"
      },
      {
        "id": "rep_llm_2",
        "type": "Continuous",
        "startOffset": "P0D",
        "endOffset": "P1D",
        "interval": "P1D",
        "minObservations": 1,
        "exitCondition": "End of study participation",
        "sourceText": "Hypoglycemic Event Reporting"
      }
    ],
    "samplingConstraints": [
      {
        "id": "sampling_1",
        "activityId": "PK_Glucagon_Sampling",
        "minPerWindow": 6,
        "windowDuration": "PT4H",
        "timepoints": [
          "Immediately before administration",
          "15 min",
          "30 min",
          "60 min",
          "120 min",
          "240 min"
        ]
      },
      {
        "id": "sampling_2",
        "activityId": "PD_Plasma_Glucose_Sampling",
        "minPerWindow": 8,
        "windowDuration": "PT4H",
        "timepoints": [
          "Pre-hypoglycemia induction",
          "During hypoglycemia induction (PG ≤75 mg/dL)",
          "Predose",
          "15 min",
          "30 min",
          "60 min",
          "120 min",
          "240 min"
        ]
      },
      {
        "id": "sampling_3",
        "activityId": "Safety_ADA_Sampling",
        "minPerWindow": 1,
        "windowDuration": "P84D",
        "timepoints": [
          "Every 12 weeks until titer returns to baseline"
        ]
      }
    ],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "WASHOUT",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "crossover study"
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "ADMISSION",
          "INSULIN_INDUCED_HYPOGLYCEMIA",
          "GLUCAGON_ADMINISTRATION",
          "POST_GLUCAGON_MONITORING",
          "END_OF_ADMISSION",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Day 1",
          "End of Admission",
          "Screening",
          "Admission",
          "Glucagon Administration Visit",
          "End of Study"
        ],
        "sourceText": "[{'condition': 'Insufficient response to glucagon administration', 'path': ['PROCEDURES_FOR_INSUFFICIENT_RESPONSE']}, {'condition': 'Inadvertently enrolled patients', 'path': ['DISCONTINUATION_FROM_STUDY_TREATMENT']}, {'condition': 'Patient lost to follow-up', 'path': ['DISCONTINUATION_FROM_STUDY']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 8; SINGLE signals: 4"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Window",
        "rationale": "WINDOW signals: 3; EPISODE signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Episode",
        "rationale": "WINDOW signals: 1; EPISODE signals: 2; SINGLE signals: 2; RECURRING signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 5; SINGLE signals: 2"
      },
      {
        "activityId": "Concomitant\nMedications",
        "executionType": "Single",
        "rationale": "WINDOW signals: 2; EPISODE signals: 1; SINGLE signals: 4"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Window",
        "rationale": "WINDOW signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Glucose Measurement",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Insulin Infusion",
        "executionType": "Single",
        "rationale": "WINDOW signals: 3; SINGLE signals: 6"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 10; SINGLE signals: 1"
      },
      {
        "activityId": "Epro",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Screening Assessment",
        "executionType": "Single",
        "rationale": "Conducted once at the start of the study to determine eligibility."
      },
      {
        "activityId": "Insulin-induced Hypoglycemia Procedure",
        "executionType": "Single",
        "rationale": "Involves a conditional workflow where insulin is administered until a target glucose level is reached, followed by glucagon administration."
      },
      {
        "activityId": "Glucose Monitoring during Procedure",
        "executionType": "Single",
        "rationale": "Requires continuous or frequent repeated measurements (e.g., every few minutes) over the duration of the induced hypoglycemia episode."
      },
      {
        "activityId": "Study Visit Assessments",
        "executionType": "Single",
        "rationale": "Standard clinical assessments performed at scheduled intervals or specific study visits as defined in the Schedule of Activities."
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutDuration": "P3D/P14D",
      "washoutRequired": true,
      "carryoverPrevention": "Patients will be administered a single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days.",
      "sourceText": "crossover study"
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_after",
        "text": "a Samples for immunogenicity, should be collected every 12 weeks (84±7 days) until the titer returns to baseline (ie, returns to within a single 2-fold dilution of the baseline titer) or until 1 year after the last dose of study treatment. A time-matched PK (glucagon) sample may be collected at the follow-up immunogenicity assessment(s) if warranted and agreed upon between both the investigator and sponsor.",
        "footnoteId": "fn_1",
        "structuredCondition": "frequency.interval(P84D, P7D).until(OR(status.baseline_return, duration.post_last_dose(P1Y)))",
        "appliesToActivityIds": [
          "Immunogenicity samples",
          "PK (glucagon) sample"
        ],
        "sourceText": "a Samples for immunogenicity, should be collected every 12 weeks (84±7 days) until the titer returns"
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "Note: if multiple procedures take place at the same time point, the following order of the procedure should be used: ECG, vital signs, and venipuncture. Plasma glucose sample should be collected as close as possible of protocol-specified time point.",
        "footnoteId": "fn_2",
        "structuredCondition": "sequence.order(ECG, vital_signs, venipuncture)",
        "appliesToActivityIds": [
          "ECG",
          "Vital signs",
          "Venipuncture",
          "Plasma glucose sample"
        ],
        "sourceText": "Note: if multiple procedures take place at the same time point, the following order of the procedure"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Treatment Success",
        "endpointType": "Primary",
        "inputs": [
          "PG",
          "PG_nadir",
          "glucagon_administration_time",
          "external_glucose_intervention"
        ],
        "timeWindow": {
          "reference": "glucagon administration",
          "duration": "PT30M"
        },
        "algorithm": "IF (external_glucose_intervention == true) THEN failure ELSE IF (PG >= 70 OR (PG - PG_nadir) >= 20) THEN success ELSE failure",
        "successCriteria": "Increase in PG to ≥70 mg/dL or an increase of ≥20 mg/dL from PG nadir within 30 minutes without additional actions to increase PG concentration",
        "sourceText": "Treatment success is defined as either an increase in PG to ≥70 mg/dL or an increase of ≥20 mg/dL from PG nadir within 30 minutes after receiving study treatment. ... The nadir is defined as the minim"
      },
      {
        "id": "ep_2",
        "name": "Secondary: Pharmacodynamic PG Characterization",
        "endpointType": "Secondary",
        "inputs": [
          "PG_concentration",
          "PG_baseline"
        ],
        "timeWindow": {
          "reference": "baseline",
          "duration": "not_specified"
        },
        "algorithm": "PG_concentration - PG_baseline",
        "successCriteria": "Evaluation of change from baseline PG concentrations",
        "sourceText": "Secondary efficacy measures will be determined from the pharmacodynamic (PD) characterization of PG profiles, including evaluation of change from baseline PG concentrations."
      },
      {
        "id": "ep_3",
        "name": "Exploratory: Subjective Hypoglycemia Symptoms",
        "endpointType": "Exploratory",
        "inputs": [
          "Edinburgh Hypoglycemia Scale score"
        ],
        "timeWindow": {
          "reference": "hypoglycemia induction and post-administration",
          "duration": "various time points"
        },
        "algorithm": "Self-reported assessment tool score",
        "successCriteria": "Assessment of subjective symptoms via Edinburgh Hypoglycemia Scale",
        "sourceText": "Subjective hypoglycemia symptoms will be assessed using a self-reported assessment tool (Edinburgh Hypoglycemia Scale; Appendix 7) during the initiation of the hypoglycemia induction, as well as at va"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Treatment Success",
        "variableType": "Composite",
        "sourceVariables": [
          "PG",
          "PG nadir"
        ],
        "derivationRule": "IF (PG > 70 mg/dL) OR (PG - PG nadir > 20 mg/dL) within 30 minutes after administration THEN Success ELSE Failure",
        "baselineDefinition": "Nadir value during hypoglycemia induction",
        "baselineVisit": "Day 1",
        "analysisWindow": "0 to 30 minutes post-administration",
        "imputationRule": "Not specified",
        "unit": "Boolean"
      },
      {
        "id": "dv_2",
        "name": "Change from Baseline PG concentrations",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "PG"
        ],
        "derivationRule": "post_dose_value - baseline_value",
        "baselineDefinition": "Predose time point between insulin infusion stop and study treatment",
        "baselineVisit": "Day 1",
        "analysisWindow": "15, 30, 60, 120 minutes post-dose",
        "imputationRule": "Not specified",
        "unit": "mg/dL"
      },
      {
        "id": "dv_3",
        "name": "Treatment-Emergent Antidrug Antibodies (TE ADA)",
        "variableType": "Categorical",
        "sourceVariables": [
          "ADA titer"
        ],
        "derivationRule": "Post-baseline titer increase of at least 2-fold (single dilution) from baseline titer",
        "baselineDefinition": "Last titer measurement prior to first dose",
        "baselineVisit": "Day -1",
        "analysisWindow": "Every 12 weeks (84±7 days) post-treatment",
        "imputationRule": "Not specified",
        "unit": "Titer"
      },
      {
        "id": "dv_4",
        "name": "Overall (Total) Hypoglycemia",
        "variableType": "Categorical",
        "sourceVariables": [
          "Documented hypoglycemia",
          "Probable symptomatic hypoglycemia",
          "Severe hypoglycemia"
        ],
        "derivationRule": "Combination of documented, probable symptomatic, and severe hypoglycemia events; excluding relative hypoglycemia; counted once per event",
        "baselineDefinition": "Not applicable",
        "baselineVisit": "Not applicable",
        "analysisWindow": "Study duration",
        "imputationRule": "Not specified",
        "unit": "Count"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Admission",
        "Insulin Induced Hypoglycemia",
        "Glucagon Administration",
        "Post Glucagon Monitoring",
        "End Of Admission",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Admission",
          "trigger": "Progress to Admission"
        },
        {
          "fromState": "Admission",
          "toState": "Insulin Induced Hypoglycemia",
          "trigger": "Progress to Insulin Induced Hypoglycemia"
        },
        {
          "fromState": "Insulin Induced Hypoglycemia",
          "toState": "Glucagon Administration",
          "trigger": "Progress to Glucagon Administration"
        },
        {
          "fromState": "Glucagon Administration",
          "toState": "Post Glucagon Monitoring",
          "trigger": "Progress to Post Glucagon Monitoring"
        },
        {
          "fromState": "Post Glucagon Monitoring",
          "toState": "End Of Admission",
          "trigger": "Progress to End Of Admission"
        },
        {
          "fromState": "End Of Admission",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Admission": "ADMISSION",
        "Insulin Induced Hypoglycemia": "INSULIN_INDUCED_HYPOGLYCEMIA",
        "Glucagon Administration": "GLUCAGON_ADMINISTRATION",
        "Post Glucagon Monitoring": "POST_GLUCAGON_MONITORING",
        "End Of Admission": "END_OF_ADMISSION",
        "End Of Study": "END_OF_STUDY",
        "Early Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "LY900018 with",
        "frequency": "QD",
        "route": "Intranasal",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "tration of glucagon. The nadir is defined as the minimum PG value at the time of or within 10 minutes following glucagon administration. Secondary  To compare the safety and tolerability of 3 mg LY90"
      },
      {
        "id": "dosing_2",
        "treatmentName": "LY900018 and",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          }
        ],
        "sourceText": "adults with T1DM and T2DM: Study IGBC, Study I8R-MC-IGBA (IGBA), and an actual use study (Study I8R-MC-B002 [B002]). Studies IGBC and IGBA demonstrated comparable safety and efficacy between 3 mg LY90"
      },
      {
        "id": "dosing_3",
        "treatmentName": "LY900018 or",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 1.0,
            "unit": "mg"
          },
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 60.0,
            "unit": "mg"
          }
        ],
        "sourceText": "be conducted to monitor bedside PG for safety. The insulin infusion will be stopped once the PG level reaches <60 mg/dL and approximately 5 minutes later patients will be administered either 3 mg LY90"
      },
      {
        "id": "dosing_4",
        "treatmentName": "Dosage Levels",
        "frequency": "QD",
        "route": "IM",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 3.0,
            "unit": "mg"
          },
          {
            "amount": 1.0,
            "unit": "mg"
          }
        ],
        "sourceText": "g glucagon administered IM (comparator). Table IGBJ.2 shows the study treatment information. Table IGBJ.2. Study Treatments Treatment Name LY900018 GlucaGen Dosage Formulation Dry powder Dry powder Do"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "Nasal Glucagon (LY900018)",
        "frequency": "Single",
        "route": "Intranasal",
        "startDay": 1,
        "durationDescription": "Single dose"
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Intramuscular Glucagon",
        "frequency": "Single",
        "route": "IM",
        "startDay": 1,
        "durationDescription": "Single dose"
      }
    ],
    "visitWindows": [
      {
        "id": "visit_1",
        "visitName": "screening",
        "targetDay": -14,
        "windowBefore": 28,
        "windowAfter": 28,
        "isRequired": true,
        "visitNumber": 1,
        "epoch": "Screening",
        "sourceText": "Patients will undergo a screening examination within 28 days prior to enrollment. Patients will be administered a single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14"
      },
      {
        "id": "visit_llm_2",
        "visitName": "Period 1, Day -1",
        "targetDay": -1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "epoch": "Period 1"
      },
      {
        "id": "visit_2",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "single dose in Periods 1 and 2, which will be separated by a washout period of 3 to 14 days. Patients will return for a follow-up visit 26 to 30 days after the last study treatment. Number of Patients"
      },
      {
        "id": "visit_3",
        "visitName": "Visit 26",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "sourceText": "a follow-up visit 26 to 30 days after the last study treatment. Number of Patients: Seventy five patients may be enrolled in order to have at least 66 patients (at least 30 patients with T1DM and"
      },
      {
        "id": "visit_7",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 5,
        "sourceText": "Samples for immunogenicity, should be collected every 12 weeks (84±7 days) until the titer returns to baseline (ie, returns to within a single 2-fold dilution of the baseline titer) or until 1 year af"
      },
      {
        "id": "visit_8",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "sourceText": "dosing visit 1 to 7 days later. For safety monitoring during the hypoglycemia induction procedure, bedside PG levels will be measured using the glucose analyzer no more than 10 minutes apart while PG "
      },
      {
        "id": "visit_9",
        "visitName": "Eos",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "sourceText": "Eosinophils Aspartate aminotransferase (AST) Basophils"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Additional Follow-up for TE ADA",
        "targetDay": null,
        "windowBefore": null,
        "windowAfter": null,
        "isRequired": false,
        "visitNumber": 8,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_6",
        "visitName": "Randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Period 1",
        "sourceText": "Randomization  Admission to CRU"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Washout",
        "targetDay": 8,
        "windowBefore": 5,
        "windowAfter": 6,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 2,
        "epoch": "Washout"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Period 2, Day -1",
        "targetDay": 14,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 2,
        "epoch": "Period 2"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Period 2, Day 1",
        "targetDay": 15,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 3,
        "epoch": "Period 2"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Follow-up/ED",
        "targetDay": 43,
        "windowBefore": 2,
        "windowAfter": 2,
        "isRequired": true,
        "visitNumber": 7,
        "targetWeek": 7,
        "epoch": "Follow-up"
      },
      {
        "id": "visit_4",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 14,
        "sourceText": "a follow-up visit 26 to 30 days after the last study treatment. Number of Patients: Seventy five patients may be enrolled in order to have at least 66 patients (at least 30 patients with T1DM and"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1",
      "method": "Randomization table",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_llm_1",
          "name": "Type of Diabetes",
          "categories": [
            "T1DM",
            "T2DM"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "I8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 23\nLY900018\n5. Study Design\n5.1.\nOverall Design\nThis is a Phase 3, multicenter, randomized, open-label, active comparator, single-dose, 2-period, \n2-"
    }
  }
}